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Abstract
Objective:
Procalcitonin (PCT) is a specific marker for differentiating bacterial from non-infective causes of
inflammation. It can be used to guide initiation and duration of antibiotic therapy in intensive care unit
(ICU) patients with suspected sepsis, and might reduce the duration of hospital stay. Limiting antibiotic
treatment duration is highly important because antibiotic over-use may cause patient harm, prolonged
hospital stay, and resistance development. Several systematic reviews show that a PCT algorithm for
antibiotic discontinuation is safe, but upfront investment required for PCT remains an important barrier
against implementation. The current study investigates to what extent this PCT algorithm is a cost-effective
use of scarce healthcare resources in ICU patients with sepsis compared to current practice.
Methods:
A decision tree was developed to estimate the health economic consequences of the PCT algorithm for
antibiotic discontinuation from a Dutch hospital perspective. Input data were obtained from a systematic
literature review. When necessary, additional information was gathered from open interviews with clinical
chemists and intensivists. The primary effectiveness measure is defined as the number of antibiotic days,
and cost-effectiveness is expressed as incremental costs per antibiotic day avoided.
Results:
The PCT algorithm for antibiotic discontinuation is expected to reduce hospital spending by circa E3503
per patient, indicating savings of 9.2%. Savings are mainly due to reductions in length of hospital stay,
number of blood cultures performed, and, importantly, days on antibiotic therapy. Probabilistic and one-way
sensitivity analyses showed the model outcome to be robust against changes in model inputs.
Conclusion:
Proven safe, a PCT algorithm for antibiotic discontinuation is a cost-effective means of reducing antibiotic
exposure in adult ICU patients with sepsis, compared to current practice. Additional resources required for
PCT are more than offset by downstream cost savings. This finding is highly important given the aim of
preventing widespread antibiotic resistance.
Background
Despite advances in medical technology and clinical care, sepsis remains a
common cause of morbidity and mortality among hospitalized patients1.
Diagnosing patients with sepsis is challenging, due to the often non-specific
presentation2. Yet, early diagnosis of infection and rapid initiation of adequate
Abbreviations:
CAP, community acquired pneumonia; ICU, intensive
care unit; IQR, interquartile range; NZA, Nederlandse
Zorg Autoriteit (Dutch Healthcare Authority); PCT, pro-
calcitonin; PSA, probabilistic sensitivity analysis; RCT,
randomized controlled trial; SD, standard deviation















































































































antimicrobial therapy are critical for successful treatment
outcome3. While the use of antibiotics has led to great
reductions in mortality and morbidity rates among sepsis
patients, antibiotic over-use should be avoided as this may
cause patient harm and prolonged hospital stay, and plays
a role in the development of widespread antibiotic
resistance4,5.
A biomarker that might improve the efficient and more
judicious use of antibiotic therapy by monitoring the pro-
gression and prognosis of bacterial infections and sepsis is
procalcitonin (PCT), a precursor of calcitonin. PCT
elevation occurs within 2–4 h after onset of the inflamma-
tory disorder, typically peaks in the second day, and falls
rapidly during clinical recovery. The magnitude and
duration of PCT elevation correlate with injury severity
and prognosis. While PCT may also be elevated in viral
and fungal infections (e.g., candidemia), this is generally
much less so than with bacterial infections6.
Several studies have assessed the added value of using
PCT to monitor and manage antibiotic therapy in septic
intensive care unit (ICU) patients, as well as in reducing
the duration of hospital stay7–9. A number of systematic
reviews have shown that a PCT discontinuation algorithm
is safe and may even improve clinical outcomes10–12. Yet,
the upfront investment for PCT testing compared to other
laboratory assays remains a barrier against implementa-
tion. Therefore, analysis of the impact of PCT testing on
in-hospital mortality, number of antibiotic days, duration
of hospitalization, and total costs of sepsis care is
warranted.
The goal of the current study is to investigate to what
extent this PCT algorithm is a cost-effective use of scarce
healthcare resources in ICU patients with sepsis compared
to current practice. A model-based analysis was performed
based on a systematic review of the literature published
until mid-2014.
In addition to previously published cost-effectiveness
analyses in this patient population13,14, this study expli-
citly considers the impact of PCT testing on hospital
length of stay and on specific clinical outcomes, and
reports costs from a non-US perspective.
Methods
A decision tree was developed to estimate the health eco-
nomic consequences of a PCT algorithm for antibiotic
discontinuation in a hypothetical population of adult
ICU patients with sepsis. The analysis was performed
from a Dutch hospital perspective. The time horizon of
the model covers the duration of a patient’s hospital stay.
All relevant health economic impacts of hospital stay and
accompanying treatment were incorporated, and com-
pared to current practice. The primary effectiveness meas-
ure was defined as the number of antibiotic days in both
the PCT strategy and current practice. In this analysis, the
total direct hospital costs were balanced against the
number of antibiotic days avoided. The Incremental
Cost Effectiveness Ratio (ICER) was expressed as incre-
mental costs per antibiotic day avoided and calculated as
the difference in direct healthcare costs, between the PCT
strategy and current practice, divided by number of anti-
biotic days avoided by the PCT strategy.
Literature review
A systematic literature review was performed to determine
to what extent a PCT algorithm affects the number of
antibiotics days, ICU length of stay, total duration of hos-
pital stay, number of days on mechanical ventilation and/
or dialysis, number of blood cultures and other lab analyses
performed, as well as patient safety which is expressed as
in-hospital mortality rates. The PubMed database was
searched for relevant articles that reported outcomes on
at least one of those parameters. The following combin-
ations of terms were searched in all fields: (algorithm OR
guideOR guidedOR based) AND (sepsisOR septic shockOR
critically ill) AND (PCT or procalcitonin) AND (antibiotic
OR antibiotics). The search was limited to articles pub-
lished in English or Dutch, and was restricted to rando-
mized controlled trials (RCTs), meta-analyses, and
systematic reviews. Articles were excluded when they
did not focus on: (1) adult patients, (2) sepsis or critically
ill patients on the ICU, and (3) the added value of a PCT
algorithm for antibiotic discontinuation. Relevant articles
were initially selected based on title and abstract. After
that, full texts were reviewed to assess whether the
papers met the inclusion criteria. The literature search
was performed in July 2014. Mean values and standard
deviations (SDs) were obtained from each of the individ-
ual studies where possible. For studies in which no mean or
SDs could be obtained, estimates of mean and SDs were
calculated according to Hozo et al.15. Following this,
weighted mean differences were calculated using Review
Manager version 5.1, combining the sample sizes of the
studies included with the mean and standard deviations
of each parameter (see Supplementary Additional file 1)
using a random effects model16.
Resource use
Data concerning the length of a patient’s hospital stay
(both on the ICU and on the general ward), as well as
the duration of antibiotic treatment in both the PCT strat-
egy and in current practice, have been derived from the
systematic literature review, as described above. In add-
ition, the change in the duration of mechanical ventila-
tion has also been derived from this review. The
percentage of patients with sepsis that are treated with
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mechanical ventilation and/or dialysis, as well as the dur-
ation of each, were derived from a retrospective database
analysis of ICU patients (age416 years) performed by
Adrie et al.17. The percentage of patients in whom a
blood culture is performed and who are finally diagnosed
as having sepsis was derived from an observational cohort
study by Shapiro et al.18. A prospective cohort study by
Mu¨ller et al.19 found that PCT measurement is an accurate
parameter for predicting bacteraemia in patients with
community acquired pneumonia (CAP), and that it has
the potential to reduce the number of blood cultures drawn
from hospitalized patients with suspected CAP. Because
pneumonia is a common site of infection for sepsis17, the
percentage of patients with suspected sepsis in whom a
blood culture was performed (both with and without
PCT) as well as the number of sets of blood cultures
taken per patient, were derived from Mu¨ller et al.19. The
number of PCT measurements performed in ICU patients
with sepsis was estimated based on RCTs by Stocker et al.20
and Schuetz et al.21. For the percentage of patients treated
with antibiotics, and the frequency at which laboratory
tests (other than the PCT test) are ordered in ICU patients
with sepsis, no single estimate could be obtained from the
literature. Therefore, those were estimated based on
qualitative interviews with intensivists (n¼ 2) and clinical
chemists (n¼ 5). An overview of the resource use param-
eters, the data sources, and assumptions that served as
input for the model is provided in Table 1.
Unit costs
The model incorporates costs of diagnostic testing (i.e.,
blood cultures, PCT testing, and other routinely performed
laboratory tests), hospital stay on ICU and general ward,
antibiotic therapy, mechanical ventilation, and dialysis.
Unit costs of blood cultures performed were derived from
publications by Mu¨ller et al.19 and Van Nieuwkoop et al.22.
Tariffs for laboratory tests were derived from the Dutch
Healthcare Authority (Nederlandse Zorgautoriteit,
NZA)23. Because no such tariff currently exists for PCT,
those costs were based on interviews with clinical chemists
and intensivists. Unit costs of hospital stay, separate for
ICU stay and stay on a general ward, mechanical ventila-
tion, and dialysis were derived from the Dutch Healthcare
Authority24 and the costing manual by Hakkaart-van
Roijen et al.25. Mean daily costs for antibiotic treatment
were obtained from Vandijck et al.26. All costs were con-
verted to 2013 Euros, using Dutch consumer price index
levels27. Because the time horizon of the model concerns
the duration of a patient’s hospital stay, lasting shorter
than 1 year, discounting is not required. A summary of
all cost inputs used in the model is provided in Table 2.
Direct hospital costs are calculated by multiplying resource
use with the accompanying unit costs.
Sensitivity analyses
To determine the joint decision uncertainty, a probabilis-
tic sensitivity analysis (PSA) was performed with 10,000
model runs, in which random samples are drawn from all
input parameters simultaneously based on pre-defined par-
ameter distributions. Distributions were parameterized
based on the observed parameter mean and on the
observed or assumed standard error28. Beta distributions
were fitted to the probability parameters, and Gamma
distributions to the resource use parameters28.
To identify which individual parameters drive the
model outcome we conducted a one-way sensitivity ana-
lysis. For each parameter, the impact of a change in the
base case value across a pre-determined range on the ICER
(i.e., costs per antibiotic day avoided) was analysed.
Parameters concerning resource use that were obtained
Table 1. Resource use. Overview of resource use in the model, showing the values used in the model, and the values applied in the one-way sensitivity
analysis in brackets. The right column shows the references used to obtain an estimate for each parameter.
Parameter Value Reference
Without PCT With PCT
Percentage treated with antibiotics* 100.0% 100.0% (75–100.0%) Expert opinion
Percentage treated with mechanical ventilation 77.0% 77.0% (57.8–96.3%) Adrie et al.17
Percentage treated with dialysis 16.0% 16.0% (12–20%) Adrie et al.17
Days on dialysis 5.0 5.0 (3.75–6.25) Adrie et al.17
Percentage of patients with (suspected) sepsis in whom a blood culture is taken 97.5% 61.4% (79.5–43.4%) Mu¨ller et al.19
Percentage of patients with blood culture performed, diagnosed as having sepsis 8.2% 8.2% (6.1–10.2%) Shapiro et al.18
Sets of blood cultures taken per patient with (suspected) sepsis 2 2 (1.5–2.5) Mu¨ller et al.19
Frequency of laboratory tests ordered per patient* 25.1 21.8 (23.4–20.1) Expert opinion
Number of PCT measurements performed per patient** 0 5 (2.5–7.5) Stocker et al.20,
Schuetz et al.21
*Expert opinions were obtained via interviews with intensivists (n¼ 2) and clinical chemists (n¼ 5).
**Because these publications both report that four-to-five PCT measurements are performed in neonates with suspected sepsis and patients with lower respiratory
tract infections, respectively, an estimate of five PCT measurements is assumed to be a conservative estimate for adult ICU patients with sepsis.
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from the literature review (ICU days, general ward days,
duration of antibiotics, and duration of mechanical venti-
lation) were all varied with 1 SD below and above the
mean.
Parameters that are not directly affected by PCT imple-
mentation but which are to some extent uncertain in both
strategies were varied, with 25% below and above the
mean in the PCT strategy. In the remaining parameters
for which an effect due to the PCT algorithm compared to
current practice was expected, this effect was increased
and decreased with 50% in the PCT strategy (Table 1).
The results of this sensitivity analysis are shown in a
tornado diagram, in which the impact of each parameter
is sorted by decreasing impact on the ICER (i.e., costs
per antibiotic day avoided).
Results
Systematic review
The search strategy initially resulted in 27 articles. Based
on the exclusion criteria, five articles were excluded
because they did not focus on sepsis or critically ill patients
at the ICU, three articles were excluded because they
focused on infants or new-borns instead of adults, and
two articles were excluded because they either focused
specifically on point-of care testing or on the comparison
with another laboratory marker instead of focusing on cur-
rent practice. Finally, this resulted in the identification of
11 reviews (of which eight meta-analyses), five original
RCTs and one economic evaluation of PCT. As the sum-
marized or pooled data from the reviews and economic
evaluation did not exactly match the data specification
as needed for our model, the reviews and the economic
evaluation were hand searched to find the relevant
original studies (RCTs) to directly obtain the relevant ori-
ginal data. In addition to five RCTs already identified, this
hand search yielded one additional RCT, amounting to a
total of six unique RCTs that were included7–9,29–31.
Figure 1 shows a flow chart of the search strategy.
Review Manager was used to calculate pooled estimates
of the duration of ICU and general ward stay, duration of
mechanical ventilation, duration of antibiotic treatment,
and in-hospital mortality. Mean values and SDs were
obtained from each of the individual studies where pos-
sible. In one study, no means or SDs were reported29.
Because the sample size of this study was sufficiently
Table 2. Cost parameters. Overview of cost parameters used in the model. The right column shows the
references used.
Parameter Value Reference
Day on general ward E500.96 Hakkaart-van Roijen et al.25
ICU admission E485.23 NZA tariffs23
Day on ICU E1811.79 NZA tariffs23
Day mechanical ventilation E386.32 NZA tariffs23
Day dialysis treatment E290.48 NZA tariffs23
Day of intravenous antibiotics E126.66 Vandijck et al.26
Set of blood cultures performed E57.84 Mu¨ller et al.19, van Nieuwkoop et al.22
Order tariff for laboratory tests E13.73 NZA tariffs23
PCT test E15.00 Expert opinion*
Other laboratory tests Varying NZA tariffs23
*Expert opinions were obtained via interviews with intensivists (n¼ 2) and clinical chemists (n¼ 5).
Figure 1. Overview of included and excluded articles. This figure shows an overview of the selection process of the studies included in the systematic review.
*Consisting of 11 reviews (of which 8 meta-analyses), and 1 economic evaluation.
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large, the median was assumed to be the best estimate of
the mean according to Hozo et al.15, who also state that
the accompanying SD can be calculated by dividing
the interquartile range (IQR) by a factor of 1.35
(SD¼ IQR/1.35)15,16.
Cost-effectiveness
Five studies reported in-hospital mortality rates and
showed no statistically significant difference between the
PCT strategy and current practice (OR¼ 0.83; 95%
CI¼ 0.49–1.38)7–9,29,31. Therefore, equal in-hospital mor-
tality rates of the PCT algorithm compared to current
practice were applied.
The PCT algorithm applied varied between studies,
using either a decrease in the peak PCT value (ranging
from 20–90%), and/or a decrease in the absolute value
of PCT (ranging from50.1 mg/L to 51 mg/L)7–9,29–31.
Regarding the primary effectiveness parameter, a statis-
tically significant reduction in antibiotic days with a
mean of 1.71 days (95% CI¼2.67, 0.74) was
found7–9,29–31. Implementation of PCT testing showed
a trend towards a decrease in overall hospital length
of stay of on average 3.34 days (95% CI¼9.38,
2.69)9,29–31 as well as a decrease in the duration of
ICU stay of 1.08 days (95% CI¼3.52, 1.36)7–9,29–31.
Therefore, a decreased length of stay on the general
ward of 3.34–1.08¼ 2.26 days is expected. Two studies
reported the effect of the PCT algorithm on the dur-
ation of mechanical ventilation30,31, with a weighted
mean increase of 0.71 days (95% CI¼1.00, 2.42)
per 12.0 days. Combined with the baseline number of
10.0 mechanical ventilation days as reported by Adrie
et al.17, the PCT strategy is associated with a weighted
increase of 0.59 mechanical ventilation days. None of
the included studies reported an effect of a PCT algo-
rithm on the duration of dialysis. A summary of the
parameter inputs based on the systematic review, as
well as the range applied in the one-way sensitivity ana-
lysis (mean 1 SD) is provided in Table 3. The forest
plots of these parameters are shown in Supplementary
Additional file 1.
A PCT algorithm to guide antibiotic discontinuation is
expected to reduce direct hospital costs per adult ICU
patient with sepsis from E37,917 to E34,414, a decrease
of E3503 (9.2%). This cost reduction is achieved with a
1.7 day reduction in duration of antibiotic use, i.e. from
11.6 to 9.9 days, and this translates into an incremental
cost saving of E2043 per antibiotic day avoided. On a
national level it is estimated that 13,000 adult ICU
patients in the Netherlands are diagnosed with sepsis
each year, indicating a potential cost saving of almost 46
million Euros per year32. An overview of those results is
shown in Table 4. Of theE3503 cost savings per patient, a
decrease of E3132 is attributable to the reduced hospital
length of stay. In the conservative scenario where the
reduction of length of stay is fully ignored, as is the accom-
panying decrease in laboratory tests that are assumed to be
performed once-daily (i.e., savings of E82), overall direct
hospital costs are still estimated to decrease withE289 per
patient (i.e. E3503  E3132  E82¼E289). Those cost
savings are mainly achieved by a decrease in the number of
blood cultures performed and the duration of antibiotic
therapy.
The decision uncertainty surrounding the incremental
cost-effectiveness ratio (ICER; point estimate E2043 per
antibiotic day avoided), as depicted in Figure 2, is low, as
82% (i.e., 8167/10 000) of Monte Carlo simulations indi-
cate that PCT reduces the duration of antibiotic treatment
while saving costs compared to current practice. Only 18%
(1771/10,000) of the simulations suggest that PCT would
be more expensive while being more effective in reducing
the number of antibiotic days.
One-way sensitivity analysis was performed to
estimate the impact of changes in individual input par-
ameters on the difference in costs of the PCT strategy
compared to current practice. Results are summarized in
a tornado diagram (Figure 3). This figure illustrates that
the net change in ICU and general ward days have the
largest impact on costs. An overview of all results of the
Table 3. Result of systematic literature review, showing the values used in the model, and the values applied in the one-way sensitivity analysis (1 SD) in
brackets. The right column shows the references used.
Parameter Value Reference
Without PCT With PCT
General ward days 11.3 9.0 (6.0–12.0) Nobre et al.9, Bouadma et al.30, Annane et al.31, Deliberato et al.29
ICU days 13.8 12.7 (11.5–13.9) Nobre et al.9, Hochreiter et al.8, Schroeder et al.7, Bouadma et al.30,
Annane et al.31, Deliberato et al.29
Days on antibiotics 11.6 9.9 (9.4–10.3) Nobre et al.9, Hochreiter et al.8, Schroeder et al.7, Bouadma et al.30,
Annane et al.31, Deliberato et al.29
Days on mechanical ventilation 10.0 10.6 (9.9–11.6) Annane et al.31, Bouadma et al.30, Adrie et al.17
Journal of Medical Economics Volume ??, Number ? Month?? 2015















































































































one-way sensitivity analysis is provided in
Supplementary Additional file 2.
Discussion
This study shows that the upfront investments in PCT
testing should not be considered in isolation, but as part
of the whole pathway of care a patient receives. Our results
indicate that, although PCT requires additional invest-
ments, those are more than offset against downstream
cost savings due to a reduced duration of hospital stay
and accompanying treatment. PCT to guide antibiotic dis-
continuation in adult ICU patients with sepsis is expected
to reduce the number of antibiotic days and save costs
without compromising patient outcomes. As such, this
study adds new insights to the very recent evidence base
regarding cost-effectiveness of PCT testing in different
patient populations and settings. For example, Harrison
and Collins (2015) found that the use of a PCT guided
treatment algorithm dominated current practice with
improved quality-of-life and decreased overall treatment
costs in a US cohort of adult ICU patients with suspected
bacterial infection and sepsis14. Notably, their analysis
does not take the impact of PCT testing on hospital
length of stay into account, which our study showed to
be a very important driver of cost savings.
A couple of aspects of our analysis warrant further
attention. First, none of the RCTs included showed a dif-
ference in in-hospital mortality for the PCT algorithm
Figure 2. Scatterplot of the results of Probabilistic Sensitivity Analysis (PSA), showing the result of 10,000 simulations and the average value.
Table 4. Model results. The costs per patient with sepsis at the ICU, split up for each of the aspects of the treatment.
Overall costs are shown both per patient and for the estimated yearly number of ICU patients with sepsis in the
Netherlands (n¼ 13 000)32. Numbers may not add up due to rounding.
Parameter Value Difference
Without PCT With PCT
Hospital stay E31,214 E28,083 E3132
General ward E5666 E4555 E1112
ICU admission and stay E25,548 E23,528 E2020
Treatment E4672 E4637 E35
Antibiotics E1465 E1248 E218
Mechanical ventilation E2974 E3157 E182
Dialysis therapy E232 E232 E0
Laboratory analyses E2030 E1694 E336
Blood cultures E1392 E1063 E329
PCT E0 E75 E75
Other laboratory tests E638 E556 E82
Total costs per patient E37,917 E34,414 E3503
Total costs in the Netherlands (n¼ 13 000) E492,916,869 E447,379,610 E45,537,259
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compared to current practice. Actually, as the pooled esti-
mate of the five RCTs reporting in-hospital mortality
shows a trend towards decreased in-hospital mortality in
the PCT group (odds ratio¼ 0.83), our model is conserva-
tive for using an equal mortality rate. Although one of the
RCTs reported an absolute increase in 60-day mortality of
3.8% in the PCT group, which may potentially question
the safety of that PCT algorithm, the authors of this study
state that ‘no patient in either group who died during days
29–60 had an infection relapse, and most deaths resulted
from complications directly related to the severity of
underlying disease’.Q2 Also, after controlling for potential
confounders, the odds ratio for death by day 60 was not
significantly different between the study groups30.
Second, cost savings associated with a PCT algorithm
were estimated to be E3503 per patient (9.2%), while
avoiding 1.7 antibiotic days (14.8%), which indicates
that the PCT algorithm dominates current practice.
Those cost savings are achieved by a reduction in ICU
and general ward length of stay, a reduction in the
number of blood cultures performed, and, importantly, a
reduction in the duration of antibiotic treatment.
Although the results of the systematic review indicate a
small (and non-significant) increase in mechanical venti-
lation days, this evidence is only based on two studies.
Because one of these studies is very small, this increase
cannot be considered conclusive. In addition, a retrospect-
ive study by Hohn et al.33 shows a decrease in the duration
of mechanical ventilation. This clearly indicates that
further research about the effect of a PCT algorithm on
the duration of mechanical ventilation is necessary.
A conservative re-analysis of the model, assuming that
the PCT strategy does not reduce ICU and general ward
length of stay, further confirms the conclusion that the
PCT algorithm to discontinue antibiotic treatment
is cost-saving. Compared to current practice, E289
per ICU patient with sepsis are saved (compared to the
E3503 in the base case scenario). These remaining cost
savings are mainly attributable to the reduced duration of
antibiotic treatment and the reduced number of blood cul-
tures performed. As blood cultures are an important tool to
confirm sepsis and because the amount of blood cultures
required to do so is assumed to be affected by the PCT test,
costs for all blood cultures performed in relation to sepsis
were included to give the best estimate of the actual
impact of PCT. An ad hoc two-way sensitivity analysis
(data not shown) shows that, in fact, when the number
of ICU days is kept equal between the strategies, the
number of regular ward days may increase with 1 day in
the PCT strategy, before this strategy becomes more costly
than current practice. Clearly, when the cost-savings due
to the length of stay reduction (i.e., E3132) would not
accrue, the decision uncertainty surrounding the model
outcomes will increase. The probabilistic sensitivity ana-
lysis performed under this conservative scenario shows a
53% probability that the PCT algorithm dominates cur-
rent practice by saving E289 per patient (compared to
82% under the base case scenario), while there is a 46%
probability that the PCT strategy is more expensive while
reducing the number of antibiotic days.
Third, the reduction in number of antibiotic days that
can be achieved by a PCT algorithm for antibiotic discon-
tinuation is highly important, not only for its impact on
total direct healthcare costs, but notably so given the rise
in antibiotic resistance. Indeed, prolonged antibiotic dur-
ation impacts the incidence of antibiotic resistance and
Clostridium difficile infections, which in this population
amounts to 4.7% and 4.6% per hospital episode, respect-
ively34–36. While not the focus of the current paper, one
could make a rough estimation of the additional indirect
Figure 3. Tornado diagram showing the effect of varying input parameters on model outcome. The lower and upper limits used in the sensitivity analysis for
each parameter are shown in the grey boxes. The parameters derived from the systematic review (duration of ICU stay, general ward stay, mechanical
ventilation, and antibiotic therapy) are varied with one SD below and above the mean. For parameters that show an effect in the PCT strategy compared to
current practice, the impact of changing this effect with 50% is shown (percentage of patients in whom a blood culture is performed). All input parameters for
which no effect was found due to the PCT strategy, a variation of 25% was used as lower and upper limit.
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cost savings of PCT testing by considering the excess
length of stay due to antibiotic resistance and C. difficile,
reportedly circa 4.6 days and 0.9 days per patient,
respectively37–39. As shorter duration of antibiotic therapy
is shown to decrease the incidence of antibiotic resistance
and C. difficile infections to 4.5% and 3.9%, respect-
ively36,40,41, this accrues additional cost savings, leading
to a new estimate of total costs per ICU patient with
sepsis of roughly E35 235 in the PCT strategy (compared
to E34 414 in the PCT base case analysis), i.e., additional
savings of E821 per patient.
Fourth, adherence to the PCT algorithm is shown to
affect its cost-effectiveness. For example, Harrison and
Collins14 showed that adherence of at least 42.3% was
needed to render their specific PCT testing strategy cost-
effective. Although we did not perform a sensitivity ana-
lysis on adherence rate, the data used in our model do
reflect sub-optimal adherence to some extent, as the stu-
dies of Bouadma et al.30 and Annane et al.31 report that
adherence in their studies was low. Explicit consideration
of adherence is recommended for further work in this area.
The results of this analysis are in line with other reviews
such as Tang et al.12, Agarwal et al.11,Q3 and Heyland et al.
42,
who conclude that PCT guided antibiotic therapy is asso-
ciated with a reduction in antibiotic usage that may reduce
overall costs of care, under certain assumptions. The latter
is important for transferring results to a specific country, as
one has to consider to what extent the current model
assumptions and inputs are representative for that country.
Because relative treatment effects are typically more trans-
ferable between developed Western countries than costs
are (due to large differences in resource use and unit costs),
ideally the model should be populated with country-spe-
cific data as much as possible to make valid per country
estimations. For example, the duration of hospital stay and
the duration of antibiotic treatment is relatively short in
the Netherlands compared to other European countries43,
thus more benefit might be expected of the PCT assay in
other European countries. Analyses for Germany and the
UK are currently ongoing, but preliminary results suggest
that the conclusions are robust across the different
countries.
Furthermore, the reduction in the duration of antibiotic
use as found in our review (1.7 days) can be considered as
consistent yet conservative compared to other studies.
Heyland et al.42 reported a weighted average decrease in
antibiotic duration of 2.14 days, and a study by Wilke
et al.13 reports an average reduction of 4 days.
Interestingly, the expected cost savings as reported in
our study are higher than those reported by Wilke et al.,
which can, amongst others, be explained by the fact that
Wilke et al. considered the effect of PCT on ICU length of
stay and on the duration of antibiotic therapy, while our
study considered the effect of PCT on the entire hospital-
ization episode. Also, in the study by Wilke et al., the costs
were derived from the German DRG calculation and
applied to a real-life patient population, which might
explain the differences in reported cost savings. Despite
differences in the magnitude of cost savings, both studies
suggest that substantial cost savings can be achieved
following PCT implementation13,42.
This study considered the use of PCT as a biomarker for
antibiotic discontinuation, not as a biomarker that guides
initiation of antibiotic therapy. Although other studies,
notably the one of Saeed et al.44, report that PCT testing
can support the decision of whether or not to start using
antibiotics in situations where there is a clinical suspicion
of infection, we conservatively did not consider this option
in our model. Interviews with intensivists and clinical
chemists in the Netherlands revealed that PCT is unlikely
to be accepted as a marker to decide on starting antibiotics,
because of the rapid increase in mortality associated with
delayed antibiotic therapy in sepsis patients. However,
it seems reasonable to argue that PCT might support
the decision to withhold antibiotics if a sub-group of
patients can be identified that only have a minor suspicion
of sepsis. If possible, this may further improve the added
value of the PCT test as a means for fighting antibiotic
resistance.
An additional recommendation for further cost-
effectiveness studies in this field is to consider the costs
of implementing a PCT algorithm. Although the test is
available for most routinely used laboratory analysers,
other additional resources may be needed to implement a
PCT algorithm (e.g., costs of educating laboratory staff
to perform the test), which will affect its incremental
cost-effectiveness, particularly in the early stages of
implementation.
Conclusions
Proven safe, we conclude that a PCT algorithm for anti-
biotic discontinuation is a cost-effective testing strategy in
adult intensive care patients with sepsis compared to cur-
rent practice. The PCT strategy as studied in this analysis
effectively reduces the duration of antibiotic therapy,
while the cost of testing is more than recouped by down-
stream cost-savings that accrue from shorter hospital
length of stay, shorter duration of antibiotic therapy, and
reduced number of blood cultures. Further research is
needed to explore the potential impact of PCT algorithms
on reducing antibiotic resistance.
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The following figures show the results of the literature review concerning the safety and 
effectiveness of a PCT algorithm for antibiotic discontinuation in adult ICU patients with sepsis. 
Pooled estimates for each parameter were obtained using Review Manager. A random effects 
model was applied. An overall estimate of the treatment effect is visualized in a forest plot for 
each parameter, including the 95% confidence interval.  
 
Figure Ia – in-hospital mortality. This table shows the impact of a PCT algorithm for antibiotic 
discontinuation on in-hospital mortality.  
 
 
Figure Ib – hospital length of stay. Impact of a PCT algorithm for antibiotic discontinuation on 
hospital length of stay. 
                Favours PCT    Favours control 
                Favours PCT    Favours control 
 Figure Ic – ICU length of stay. Impact of a PCT algorithm for antibiotic discontinuation on ICU 
length of stay. 
 
 
Figure Id – antibiotic use. Impact of a PCT algorithm for antibiotic discontinuation on duration 
of antibiotic treatment.  
 
 
Figure Ie – mechanical ventilation. Impact of a PCT algorithm for antibiotic discontinuation on 
duration of mechanical ventilation. 
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Table I – one-way sensitivity analysis results. This table shows the result of the one-way 
sensitivity analysis. Both the base case input parameter as well as the lower and upper limit, and 








Base case  - € - 3,462 
Effect on regular ward days 9.0 6.0 
12.0  
€ - 4,975 
€ - 1,951 
Effect on ICU days 12.7 11.5 
13.9 
€ - 5,672 
€ - 1,251 
Percentage receiving antibiotics 100.0% 75.0% € - 3,774 
Effect on antibiotic days 9.9 9.4 
10.3 
€ - 3,523 
€ - 3,400 
Effect on percentage mechanical 
ventilation 
77.0% 57.8% 
               96.3% 
€ - 4,249 
€ - 2,674 




€ - 3,681 
€ - 3,172 




€ - 3,520 
€ - 3,404 
Number of days on dialysis therapy 5.00 3.75 
6.25 
€ - 3,520 
€ - 3,404 
Effect on percentage of patients in 
whom a blood culture is performed 
61.4% 79.5% 
43.4% 
€ - 3,207 
€ - 3,717 




€ - 3,679 
€ - 3,244 
Blood cultures performed in patients 
diagnosed as having sepsis 
8.2% 6.1% 
10.2% 
€ - 3,111 
€ - 3,672 




€ - 3,421 
€ - 3,502 




€ - 3,499 
€ - 3,424 
 
